2024-09-16 10:19:27
While <a href="https://www.archyde.com/soon-a-vaccine-against-bronchiolitis-in-infants/” title=”Soon a vaccine against bronchiolitis in infants?”>Beyfortus helped prevent 5,800 baby hospitalizations for bronchiolitis last year, the campaign is starting again with a new option: the possibility of vaccinating pregnant women.
Published on 09/16/2024 12:19
Reading time: 2 min This year, France will receive nearly 600,000 doses of Beyfortus, three times more than last year. (RICCARDO MILANI / HANS LUCAS via AFP)
The campaign to protect babies against bronchiolitis starts on Monday, September 16. Like last year, parents will be able to choose to immunize their child against severe forms of the disease this winter with Beyfortus, an antibody that has been on the market for a year. A new option now also exists with a vaccine for pregnant women.
At the Béclère hospital in Clamart, in the Paris region, the pediatric emergency room overwhelmed by the arrival of babies suffering from severe forms of bronchiolitis seems to be a thing of the past. This is what Professor Vincent Gajdos is delighted about. The pediatrician confirms that last winter, the arrival of Beyfortus finally changed the situation: “It was quite an extraordinary year for us because it was the first time that we were able to prevent an epidemic that we had known about for 25 years.”
“We saw a clear decrease in the number of emergency room visits and hospitalizations for bronchiolitis. We were able to observe an 80% reduction in the risk of developing bronchiolitis for babies who had received this monoclonal antibody.”
Prof. Vincent Gajdos
to franceinfo
According to Public Health France, this antibody produced by Sanofi and Astrazeneca and widely acclaimed by parents, has prevented 5,800 hospitalizations of babies. “This year we start again even more motivated with two possibilities”says Professor Alexandra Benachi, head of the obstetrics and gynecology department.
In fact, this year the option is either Beyfortus or Abrysvo, a brand new vaccine from Pfizer that is injected into pregnant women. In this case, the baby is protected even before birth. “There is no preference, we warn all patients at the end of pregnancy that this possibility exists. Some prefer to be vaccinated themselves rather than giving an injection to their child, others prefer Beyfortus which has already worked well last year.”
Similar effectiveness, few side effects, health authorities also do not issue a preference between these two options, it will be up to the parents to choose. Moreover, neither one nor the other is mandatory. Health professionals also remind us that to avoid bronchiolitis this fall and winter, we must not forget the barrier gestures and prevent everyone around us from cuddling the newborns.
1726482440
#Beyfortus #Abrysvo #campaign #immunization #babies #starts #Monday
Parents can choose what they feel is best for their child.
Table of Contents
Protecting Babies from Bronchiolitis: Beyfortus and Abrysvo Offer New Hope
As the winter season approaches, parents in France are gearing up to protect their babies from bronchiolitis, a common and potentially serious respiratory infection. Last year, the introduction of Beyfortus, an antibody produced by Sanofi and Astrazeneca, marked a significant milestone in the fight against this disease. This year, a new option is available: Abrysvo, a vaccine from Pfizer that can be administered to pregnant women to protect their babies even before birth.
The Success of Beyfortus
The campaign to immunize babies against severe forms of bronchiolitis starts on September 16th, and parents will have the option to choose between Beyfortus and Abrysvo. Last year, Beyfortus helped prevent 5,800 baby hospitalizations for bronchiolitis, a remarkable 80% reduction in the risk of developing the disease. Professor Vincent Gajdos, a pediatrician at the Béclère hospital in Clamart, attests to the antibody’s effectiveness: “We saw a clear decrease in the number of emergency room visits and hospitalizations for bronchiolitis. It was an extraordinary year for us.”
The New Option: Abrysvo
This year, Abrysvo offers a new way to protect babies from bronchiolitis. The vaccine is administered to pregnant women, providing protection to the baby even before birth. Professor Alexandra Benachi, head of the obstetrics and gynecology department, notes that both options are available to parents, with no preference expressed by health authorities. “Some prefer to be vaccinated themselves rather than giving an injection to their child, others prefer Beyfortus which has already worked well last year.”
Similar Effectiveness, Few Side Effects
Both Beyfortus and Abrysvo have shown similar effectiveness in preventing bronchiolitis, with few side effects reported. Health professionals remind parents that neither option is mandatory, and it is ultimately up to them to decide which one to choose.
Additional Measures to Prevent Bronchiolitis
While vaccination is an essential step in preventing bronchiolitis, health professionals emphasize the importance of additional measures to protect babies. Barrier gestures, such as washing hands regularly and avoiding close contact with anyone showing symptoms of illness, remain crucial in preventing the spread of the disease. It is also essential to advise family and friends to avoid cuddling newborns, as this can easily transmit the infection.
Conclusion
The launch of Abrysvo alongside Beyfortus marks a significant step forward in the fight against bronchiolitis. With two options available, parents have more choices than ever before to protect their babies from this potentially serious disease. By combining vaccination with good hygiene practices and common sense measures, parents can significantly reduce the risk of bronchiolitis and ensure a healthy start for their babies.
Key Takeaways:
Beyfortus helped prevent 5,800 baby hospitalizations for bronchiolitis last year.
Abrysvo is a new vaccine that can be administered to pregnant women to protect their babies from bronchiolitis.
Both options have shown similar effectiveness and few side effects.
Neither option is mandatory, and
Less common and less severe in young children.
Protecting Babies from Bronchiolitis: New Vaccine Option for Pregnant Women
As the winter season approaches, parents and healthcare professionals alike are gearing up for the annual battle against bronchiolitis, a common and potentially life-threatening respiratory illness affecting young children. Last year, the introduction of Beyfortus, a monoclonal antibody, marked a significant breakthrough in preventing severe forms of bronchiolitis, with 5,800 fewer hospitalizations reported. This year, a new vaccine option is available, offering pregnant women the chance to protect their babies from bronchiolitis even before birth.
Beyfortus: A Proven Success
Beyfortus, developed by Sanofi and Astrazeneca, has been on the market for a year, and its impact has been nothing short of remarkable. According to Professor Vincent Gajdos, a pediatrician at Béclère hospital in Clamart, France, the arrival of Beyfortus last winter was a game-changer. “It was quite an extraordinary year for us because it was the first time that we were able to prevent an epidemic that we had known about for 25 years,” he said. The data speaks for itself: an 80% reduction in the risk of developing bronchiolitis was observed in babies who received the antibody.
A New Option: Abrysvo Vaccine for Pregnant Women
This year, parents have an additional option to protect their babies from bronchiolitis. Abrysvo, a vaccine developed by Pfizer, is administered to pregnant women, providing their unborn babies with immunity against the disease. Professor Alexandra Benachi, head of the obstetrics and gynecology department, explained that both options are available, and there is no preference between them. “Some prefer to be vaccinated themselves rather than giving an injection to their child, others prefer Beyfortus, which has already worked well last year,” she said.
Similar Effectiveness, Few Side Effects
Health authorities have emphasized that both Beyfortus and Abrysvo have similar efficacy in preventing bronchiolitis, with minimal side effects reported. The choice between the two ultimately rests with the parents, and neither is mandatory. Healthcare professionals stress the importance of continuing to practice good hygiene and barrier gestures to prevent the spread of bronchiolitis, particularly around newborns.
A Step Forward in Maternal and Child Health
The availability of these two options marks a significant step forward in the fight against bronchiolitis, a disease that affects thousands of children every year. By empowering parents with choices and providing them with effective tools to protect their babies, we can work towards a future where bronchiolitis is